Clinical Trial Update: Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating talazoparib plus avelumab in metastatic renal cell carcinoma, including fumarate hydratase–deficient and succinate dehydroge…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fumarate Hydratase-deficient Renal Cell Carcinoma
• Renal Cell Carcinoma
• Succinate Dehydrogenase-deficient Renal Cell Carcinoma

Drugs mentioned

• Avelumab (avelumab)
• Talazoparib (talazoparib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Metastatic Renal Cell Carcinoma, Fumarate Hydratase Deficient Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2024-12-27